Literature DB >> 23010833

Trichomegaly of the eyelashes during therapy with epidermal growth factor receptor inhibitors: report of 3 cases.

Gabriella Fabbrocini1, Luigia Panariello, Sara Cacciapuoti, Dario Bianca, Fabio Ayala.   

Abstract

A wide spectrum of skin toxicities has been described in patients receiving epidermal growth factor receptor (EGFR), inhibitors, including papulopustular rash, xerosis and fissures, pruritus, mucositis, paronychia, and hair changes.Trichomegaly of the eyelashes is a rare adverse effect of EGFR inhibitor therapy and is characterized by a paradoxical overgrowth of eyelashes. We present 3 cases of trichomegaly occurred during EGFR inhibitor therapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23010833     DOI: 10.1097/DER.0b013e31826e45d7

Source DB:  PubMed          Journal:  Dermatitis        ISSN: 1710-3568            Impact factor:   4.845


  4 in total

Review 1.  Ocular Toxicity of Targeted Anticancer Agents.

Authors:  Blake H Fortes; Prashant D Tailor; Lauren A Dalvin
Journal:  Drugs       Date:  2021-03-31       Impact factor: 9.546

2.  Epidermal growth factor receptor inhibitors related trichomegaly of Eyelashes.

Authors:  Vinayak V Maka; Hithashree Rajanna; Anil Kumar Narasiyappah; Rohith Chitrapur; Nalini Kilara
Journal:  Oxf Med Case Reports       Date:  2014-08-05

Review 3.  Ocular side effects of biological agents in oncology: what should the clinician be aware of?

Authors:  Tobias Hager; B Seitz
Journal:  Onco Targets Ther       Date:  2013-12-24       Impact factor: 4.147

4.  Extreme Phenotype of Epidermal Growth Factor Receptor Inhibitor-induced Destructive Folliculitis.

Authors:  Florian Anzengruber; Barbara Meier; Julia-Tatjana Maul; Katrin Kerl; Lars E French; Alexander A Navarini
Journal:  Int J Trichology       Date:  2016 Oct-Dec
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.